Company Overview and News

 
NZX shuts down Elevation Capital's 'unreasonable' demands

2018-10-08 radionz.co.nz
The NZX board has knocked back a list of demands by Elevation Capital as the shareholder scales up efforts for reform of the market operator.
NZSTY NZSTF

 
Cash drought - why can't small businesses get the capital they need to grow?

2018-10-04 nzherald.co.nz
Just a few years ago, the only way a New Zealand entrepreneur could get investment in their business was to "pick up the phone and call the local rich guy", muses Enterprise Angels executive director Bill Murphy.
NZSTY NZSTF

 
Shareholder takes NZX to task over costs and strategic plan

2018-10-02 radionz.co.nz
A shareholder in NZX is fed up with the market operator's progress in implementing changes that will turn its fortunes around and has published an alternative strategic plan for it to follow.
NZSTY NZSTF

 
Stock Takes: There's nothing passive about passive funds

2018-09-13 nzherald.co.nz
Anyone doubting the power of exchange traded funds (ETFs) need look no further than trading this week, when the sharemarket rallied by 2 per cent in just one day.
NZSTY NZSTF

 
'A period of fear and greed' - The Lehman crash remembered

2018-09-13 nzherald.co.nz
"It was a frightening time ... a period of fear and greed," says Rickey Ward, NZ equity manager at JBWere.
NZSTY NZSTF

 
NZX and Nasdaq explore opportunities

2018-09-12 radionz.co.nz
The stock exchange is looking at an alliance with Wall Street's tech-laden Nasdaq to explore opportunities.
NZSTY NZSTF

 
New Zealand's NZX partners with Nasdaq

2018-09-11 reuters
Sept 12 (Reuters) - New Zealand’s bourse operator NZX Ltd said on Wednesday it had agreed to cooperate with U.S. stock exchange Nasdaq Inc to explore opportunities in dual listings, depository receipts and other areas.
NDAQ NZSTY NZSTF

 
UPDATE 1-New Zealand's NZX partners with Nasdaq

2018-09-11 reuters
(Reuters) - New Zealand’s bourse operator NZX Ltd (NZX.NZ) said on Wednesday it had agreed to cooperate with U.S. stock exchange Nasdaq Inc (NDAQ.O), as the company vies to generate new offerings and targets overseas businesses amidst a dearth of listings.
NDAQ NZSTY NZSTF

 
NZ share trading to resume tomorrow after technical fault

2018-08-28 nzherald.co.nz
The NZX said the fault that disrupted trading on the exchange today had been resolved, and that normal business would resume tomorrow.
NZSTY NZSTF

 
Tim Preston: It's time to start supporting our SMEs

2018-08-27 nzherald.co.nz
It is time participants in New Zealand's listed capital markets stopped playing the blame game and take responsibility for fixing the lack of new listings on the NZX by supporting our small and emerging companies.
NZSTY NZSTF

 
Big Read: Joanna Lawn, the savvy deal maker revamping the NZX

2018-07-15 nzherald.co.nz
When Joanna Lawn began her first job in a London financial dealing room, her boss almost kicked her out.
DB NZSTY NZSTF

 
QEX Logistics sees 42% revenue boost after listing

2018-07-12 nbr.co.nz
QEX Logistics has produced higher annual revenue than expected, as demand from China for milk powder and infant formula grows.
NZSTY NZSTF

4
PushPay in trading halt as Crowther sells $108m stake, exits

2018-06-18 nbr.co.nz
PushPay shares remain on a trading halt for a bookbuild to sell co-founder Eliot Crowther's 9.03% stake, valued at $108 million on the company's pre-halt price.
DB NZSTY NZSTF

4
Comment: Five steps to stronger capital markets

2018-06-10 nzherald.co.nz
If the New Zealand economy were a human body, then we can think of capital as the oxygen required to sustain life.
NZSTY NZSTF MSCI

 
Brian Gaynor: The NZX must take stock before it's left behind

2018-06-08 nzherald.co.nz
The World Federation of Exchanges (WFE), which was established in 1961 and is based in London, is the industry association for global stock exchanges and clearing houses.
ASXFF NZSTY ASXFY NZSTF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 629506106